Consumer Health COVID19

Promising COVID oral antiviral being co-researched by Healion Bio and FUJIFILM Toyama

Dr. Sina Bavari, co-founder of Healion Bio, noted "Highly contagious pathogens can rarely be stopped by testing, vaccines, and hospital therapeutics alone....

 April 30, 2022 | News

Chiropractors, Researchers Begin the Hunt for Long COVID Therapy

Leading clinical chiropractic physicians, including those who have experienced in managing WFH pain for COVID-19, are collecting early data with researcher...

 April 25, 2022 | News

Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine

Data from this combination trial will inform planned Phase 2 dose confirmation trial, scheduled to begin by the end of 2022 Immune response confirmed in...

 April 22, 2022 | News

Novavax Announces Approval of Nuvaxovid™ COVID-19 Vaccine for Primary and Booster Immunization in Japan

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious dise...

 April 20, 2022 | News

Novavax and SII Receive EUA for Novavax' COVID-19 Vaccine in Thailand

 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectiou...

 April 11, 2022 | News

New very-high-sensitivity rapid antigen test kits hit Australian market

 Medriva; https://medriva.com, a leading global manufacturer of COVID-19 testing and vaccination products, announced the Australian availability ...

 April 08, 2022 | News

Seegene's Allplex™ RV Master Assay receives Australian TGA approval, European CE-IVD mark

Test detects 21 targets for 19 respiratory viruses in single tube, including COVID-19 and flu Assay result of Seegene's decades-long know-how, applies D...

 April 07, 2022 | News

CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China

Pre-clinical trial results showed that CanSinoBIO's COVID-19 mRNA vaccine can induce high-titer neutralizing antibody levels against multiple SARS-CoV-2 va...

 April 05, 2022 | News

CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China

Pre-clinical trial results showed that CanSinoBIO's COVID-19 mRNA vaccine can induce high-titer neutralizing antibody levels against multiple SARS-CoV-2 va...

 April 04, 2022 | News

Novavax Submits Request to Expand Conditional Marketing Authorization of COVID-19 Vaccine in the EU to Adolescents (Ages 12-17)

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious dise...

 April 01, 2022 | News

Novavax Announces Participation in Two Booster Studies Using its COVID-19 Vaccine

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious dise...

 March 28, 2022 | News

iMeddy provides free video medical consultation to COVID-19 patients

The service is being carried out in two phases. The first phase, which is now complete, targeted low-income families, while the upcoming second phase will ...

 March 25, 2022 | News

CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia

The MOH Malaysia recommends using Convidecia™ as a heterologous booster for individuals aged 18 and above who have been administered two doses of ina...

 March 23, 2022 | News

Novavax and SII Announce First EUA of Novavax' COVID-19 Vaccine in Adolescents ≥12 to <18 in India

Covovax™ (SARS-CoV-2 rS Protein (COVID-19) recombinant spike protein Nanoparticle Vaccine) is the first protein-based COVID-19 vaccine authorized&n...

 March 23, 2022 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close